Vimseltinib is a Small Molecule owned by Deciphera Pharmaceuticals, and is involved in 3 clinical trials, which are ongoing.
Vimseltinib (DCC-3014) acts by blocking FMS kinase. The two known ligands of FMS, macrophage colony-stimulating factor (M-CSF or CSF-1) and interleukin 34 (IL-34) (5), activate signaling through the receptor in a similar fashion but differ in their developmental and tissue-specific expression patterns activity. The Ligand-stimulated FMS tyrosine phosphorylation regulates the survival, proliferation, and differentiation of macrophage lineages. This is a primary mechanism whereby tumor microenvironment associated macrophages mediate invasiveness and metastasis of a variety of cancers. The drug candidate blocks the actions of pro-tumoral macrophages in the tumor microenvironment.
The revenue for Vimseltinib is expected to reach a total of $816m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vimseltinib NPV Report.
Vimseltinib is currently owned by Deciphera Pharmaceuticals.
Vimseltinib (DCC-3014) is under development for the treatment of advanced malignancies such as solid tumors and tenosynovial giant cell tumor. It is administered orally. The drug candidate acts by targeting the FMS kinase (also known as CSF1R). It is developed based on kinase inhibitor technology. It was also under development for the treatment of glioma, renal cell carcinoma and osteolytic cancer.
It was also under development for the treatment of acute myeloid leukemia (AML), colorectal cancer, bone metastasis, prostate cancer, myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL).
Deciphera Pharmaceuticals Overview
Deciphera Pharmaceuticals is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. The company’s products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US
The company reported revenues of (US Dollars) US$96.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$42.1 million in FY2020. The operating loss of the company was US$300.1 million in FY2021, compared to an operating loss of US$271.2 million in FY2020. The net loss of the company was US$300 million in FY2021, compared to a net loss of US$266.5 million in FY2020. The company reported revenues of US$36 million for the third quarter ended September 2022, an increase of 10.7% over the previous quarter.
Quick View – Vimseltinib
|Highest Development Stage|